Purple Biotech Financials

PPBT Stock  USD 2.74  0.55  25.11%   
Based on the key indicators obtained from Purple Biotech's historical financial statements, Purple Biotech may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Purple Biotech's Net Invested Capital is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 363.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024. Key indicators impacting Purple Biotech's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.30.34
Fairly Down
Slightly volatile
Current Ratio2.092.198
Notably Down
Slightly volatile
The essential information of the day-to-day investment outlook for Purple Biotech includes many different criteria found on its balance sheet. An individual investor should monitor Purple Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Purple Biotech.

Net Income

(18.89 Million)

  
Understanding current and past Purple Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Purple Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Purple Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Purple Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Purple Biotech. Check Purple Biotech's Beneish M Score to see the likelihood of Purple Biotech's management manipulating its earnings.

Purple Biotech Stock Summary

Purple Biotech competes with Pluri, BioLineRx, Enlivex Therapeutics, Anebulo Pharmaceuticals, and Pmv Pharmaceuticals. Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Foreign Associate
  Israel
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS74638P1093
CUSIP74638P109 49803V107 49803V206 74638P208
LocationIsrael
Business Address4 Oppenheimer Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitepurple-biotech.com
Phone972 3 933 3121
CurrencyUSD - US Dollar

Purple Biotech Key Financial Ratios

Purple Biotech Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets14.7M83.8M70.2M54.6M44.3M32.4M
Other Current Liab1.1M1.7M2.6M4.7M3.5M2.2M
Net Debt(4.2M)(10.4M)(10.1M)(14.5M)(14.1M)(13.4M)
Retained Earnings(49.5M)(77.5M)(95.9M)(117.6M)(137.5M)(130.6M)
Accounts Payable1.2M1.2M1.5M2.1M3.5M3.7M
Cash4.4M11.2M10.9M15.0M14.5M8.4M
Other Current Assets1.9M977K1.3M1.1M376K357.2K
Total Liab3.9M4.1M5.1M7.5M10.0M10.5M
Total Current Assets8.3M59.3M48.5M33.3M15.8M20.9M
Other Liab285K265K292K145K130.5K124.0K
Net Tangible Assets4.2M58.9M44.3M26.2M30.2M24.0M
Net Invested Capital10.4M79.4M64.8M46.9M34.2M39.9M
Net Working Capital4.8M56.2M44.2M26.2M8.6M8.2M

Purple Biotech Key Income Statement Accounts

The reason investors look at the income statement is to determine what Purple Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense181K61K212K126K2.2M2.3M
Operating Income(7.2M)12.6M(17.9M)(22.6M)22.3M23.4M
Ebit(7.2M)(28.6M)(17.7M)(21.7M)(22.4M)(21.3M)
Research Development2.7M7.5M11.8M16.3M17.0M17.9M
Ebitda(7.6M)(28.4M)(17.5M)(21.5M)(22.2M)(21.1M)
Income Before Tax(5.9M)(28.1M)(17.8M)(21.8M)(20.0M)(19.0M)
Net Income(6.1M)(12.4M)(18.5M)(20.8M)(19.9M)(18.9M)
Income Tax Expense216K(15.7M)637K(935K)(97K)(101.9K)
Net Interest Income70K193K108K843K(1.7M)(1.6M)
Interest Income151K254K320K969K474K344.4K
Minority Interest438K363K84K92K97K92.2K
Gross Profit999.9K765K(551K)(1.1M)(196K)(186.2K)

Purple Biotech Key Cash Accounts

201920202021202220232024 (projected)
Free Cash Flow(5.6M)(12.2M)(15.2M)(17.0M)(19.2M)(18.3M)
Other Non Cash Items(1.5M)15.5M(108K)(843K)(931K)(884.5K)
Capital Expenditures11K156K115K228K3K2.9K
Net Income(5.9M)(28.1M)(17.8M)(21.8M)(19.9M)(18.9M)
Change In Cash(778K)6.9M(357K)4.1M(541K)(514.0K)
End Period Cash Flow4.4M11.2M10.9M15.0M14.5M8.4M
Depreciation179K235K231K201K197K129.2K
Investments(449K)(49.6M)13.2M19.9M13.9M14.6M
Change To Netincome(249K)18.0M2.4M1.5M1.7M1.6M

Purple Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Purple Biotech competition to find correlations between indicators driving Purple Biotech's intrinsic value. More Info.
Purple Biotech is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers . At this time, Purple Biotech's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Purple Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Purple Biotech Systematic Risk

Purple Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Purple Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Purple Biotech correlated with the market. If Beta is less than 0 Purple Biotech generally moves in the opposite direction as compared to the market. If Purple Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Purple Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Purple Biotech is generally in the same direction as the market. If Beta > 1 Purple Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Purple Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Purple Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Purple Biotech growth as a starting point in their analysis.

Price Earnings To Growth Ratio

42.43

At this time, Purple Biotech's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Purple Biotech November 26, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Purple Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Purple Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Purple Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Purple Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Purple Biotech's daily price indicators and compare them against related drivers.

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.